VectorBuilder Announces Highly Stable MuteFree™ AAV for Gene Therapy
NQ Score
84/100
N1 Content Completeness
9
AI Summary (NQ-processed)
VectorBuilder has developed the MuteFree™ AAV vector to solve ITR sequence instability in gene therapy manufacturing. This technology reduces the mutation rate to 0% using standard E. coli, significantly improving viral yield and reliability.
AI Analysis
Frequently Asked Questions
- Q: What is MuteFree™ AAV?
- A: A vector system developed by VectorBuilder that resolves the instability of AAV vector ITR sequences, enabling stable manufacturing.
- Q: What are the main benefits of this technology?
- A: It reduces the mutation rate of ITR sequences to 0% in standard manufacturing environments, improving viral yield and quality uniformity.
- Q: Why is the stability of ITR sequences important?
- A: Because incomplete ITR sequences can lower viral packaging efficiency and gene expression levels, negatively impacting therapeutic efficacy.